Biogen Launches Tender Offer to Acquire Apellis for $41/Share Cash Plus CVRs, Valuing Company at $5.6 Billion

summarizeSummary

Biogen Inc. has commenced a tender offer to acquire Apellis Pharmaceuticals, Inc. for $41.00 per share in cash plus contingent value rights (CVRs) of up to $4.00 per share, totaling approximately $5.6 billion in equity value.

check_boxKey Events

• Tender Offer Commenced

  Biogen Inc. has launched a tender offer to acquire all outstanding shares of Apellis Pharmaceuticals, Inc.

• Acquisition Price

  Shareholders will receive $41.00 per share in cash, representing an 86% premium to the 90-day volume-weighted average stock price and a 35% premium to the 52-week high stock price.

• Contingent Value Rights (CVRs)

  In addition to cash, shareholders will receive one non-transferable CVR per share, entitling holders to potential payments of up to an aggregate of $4.00 in cash upon achievement of specified global net sales milestones for SYFOVRE® by 2031.

• Total Equity Value

  The transaction is valued at approximately $5.6 billion in upfront equity consideration.

auto_awesomeAnalysis

This SC TO-C filing formally initiates the tender offer by Biogen to acquire Apellis Pharmaceuticals, following the definitive merger agreement announced concurrently. The offer of $41.00 per share in cash, combined with contingent value rights (CVRs) potentially worth up to an additional $4.00 per share, represents a substantial premium for Apellis shareholders. The CVRs are tied to future global net sales milestones for SYFOVRE®, providing an upside linked to the product's commercial success. The unanimous recommendation by Apellis's Board and the support agreements from key shareholders, representing approximately 14% of outstanding shares, indicate strong internal backing for the transaction. This acquisition is a transformative event for Apellis, offering a significant return to shareholders and integrating its immunology and rare disease assets into Biogen's portfolio, with a focus on accelerating Biogen's expansion into nephrology.